Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +1.27% | -0.62% | +12.77% |
03-15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
03-14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Evolution of the average Target Price on aTyr Pharma, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering aTyr Pharma, Inc.
RBC Capital Markets | |
Piper Sandler | |
Oppenheimer | |
Roth MKM | |
HC Wainwright | |
Roth Capital Partners | |
JonesTrading Institutional Services | |
Laidlaw & Co. |
EPS Revisions
- Stock Market
- Equities
- LIFE Stock
- Consensus aTyr Pharma, Inc.